The tumor suppressor p53 function is frequently impaired in human cancers, and it is thought that p53 mutations play a pivotal role in the adenoma–carcinoma transition [15,16] and occur in 60% of reported CRCs [17]. This evidence concerns the gene TP53 and carcinoma.